Grafa News and Videos — Page 663

Ingredion (NYSE:INGR) announced on Monday a definitive agreement to acquire the UK-based ingredients specialist Tate & Lyle in an all-cash transaction.

Alliance Resource Partners (NASDAQ:ARLP) announced on June 8, 2026, that it has entered into definitive agreements to acquire general partner and limited partner interests in AllDale Minerals III, LP and AllDale Minerals IV, LP (collectively, “AllDale III & IV”) for approximately $206.2 million.

FOX (NASDAQ:FOX) has finalized a multi-year agreement with the National Football League to serve as a broadcast partner for NFL content in Mexico.

Seaport Therapeutics (NASDAQ:SPTX) announced its financial results for the first quarter ended March 31, 2026, marking a pivotal period of transition for the Boston-based biotech as it enters the public markets.

Incyte (NASDAQ:INCY) announced today that it has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for an upfront payment of $1.25 billion.

RedHill Biopharma (NASDAQ:RDHL) announced on June 8, 2026, that it has officially commenced recognition and enforcement proceedings in South Korea to collect on a final judgment awarded by the New York Supreme Court against Kukbo.

SUNation Energy (NASDAQ:SUNE) and Suniva announced on June 8, 2026, the signing of a definitive reverse merger agreement.

Graham (NYSE:GHM) announced its financial results for the fourth quarter and full fiscal year ended March 31, 2026, marking a period of record-setting performance for the Batavia, New York-based manufacturer.

AECOM (NYSE:ACM) announced today that it has been awarded a new contract to provide comprehensive architecture and engineering (A/E) services to the U.S. Department of Homeland Security (DHS).

Pfizer (NYSE:PFE) announced on June 8, 2026, that the U.S. Food and Drug Administration (FDA) has granted an expanded indication for HYMPAVZI® (marstacimab-hncq). The therapy is now approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with hemophilia A or B, both with and without inhibitors.